GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » ROIC %

Radiopharm Theranostics (Radiopharm Theranostics) ROIC % : -77.54% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Radiopharm Theranostics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -77.54%.

As of today (2024-05-23), Radiopharm Theranostics's WACC % is 10.27%. Radiopharm Theranostics's ROIC % is -63.68% (calculated using TTM income statement data). Radiopharm Theranostics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Radiopharm Theranostics ROIC % Historical Data

The historical data trend for Radiopharm Theranostics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics ROIC % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
ROIC %
-32.25 -52.54

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % -30.28 -32.59 -53.26 -49.73 -77.54

Competitive Comparison of Radiopharm Theranostics's ROIC %

For the Biotechnology subindustry, Radiopharm Theranostics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's ROIC % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's ROIC % falls into.



Radiopharm Theranostics ROIC % Calculation

Radiopharm Theranostics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROIC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=-23.16 * ( 1 - -0.11% )/( (43.459 + 44.805)/ 2 )
=-23.185476/44.132
=-52.54 %

where

Radiopharm Theranostics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-33.068 * ( 1 - -0.13% )/( (44.805 + 40.596)/ 2 )
=-33.1109884/42.7005
=-77.54 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (OTCPK:RDPTF) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Radiopharm Theranostics's WACC % is 10.27%. Radiopharm Theranostics's ROIC % is -63.68% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Radiopharm Theranostics ROIC % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022